Is There a “Brain Pacemaker” for Dogs with Epilepsy? What the Science Actually Offers in 2026

If your dog has drug-resistant epilepsy, you’ve probably asked yourself this question — maybe with the same frustration many of us owners feel: with all the technology we have, how is there no “pacemaker” for my dog’s brain, the way there is for the heart?

Good news: there is. It’s called vagus nerve stimulation (VNS), it’s been used in humans for over 25 years, and as of 2026 there are devices designed specifically for dogs.

Here’s what it is, how it works, who it’s for, what the real results show, and what’s coming — with the scientific sources on the table.

First, the exact analogy: the brain pacemaker

A cardiac pacemaker is a small device implanted under the skin that sends electrical pulses regulating the heart’s rhythm. VNS works with the same logic, aimed at a different organ:

A pulse generator (about the size of a small coin) is implanted under the skin of the neck
A wire connects to the vagus nerve — one of the main communication “cables” between the body and the brain
The device sends programmed electrical pulses that modulate the brain’s electrical activity

VNS has been used in over 100,000 humans with epilepsy since FDA approval in 1997. And the scientific evidence shows dogs respond as well as — or better than — humans.

What are the real results in dogs?

The two most important studies in canine epilepsy come from Langford Veterinary Services at the University of Bristol (UK), published by veterinarians Harcourt-Brown and Carter:

Long-term study (2023, Journal of Veterinary Internal Medicine): 12 dogs with drug-resistant idiopathic epilepsy received VNS implants. The results, with full honesty:

5 of the 12 dogs were euthanized within the first year — refractory epilepsy is a serious disease, and these were among the hardest cases
All 7 dogs that continued achieved a greater than 50% reduction in seizure frequency
3 of those 7 became seizure-free
The effect was cumulative: it took 2-3 years to build fully

Dosing study (2021): the most common side effect is coughing (seen in 11 of 14 dogs), and they learned that increasing the current slowly (every 1-3 weeks) prevents the cough from becoming intolerable.

An honest translation of these numbers: VNS is not a cure and not a quick rescue — it’s a slow-building therapy, comparable to what adding a second medication achieves, but without the pharmaceutical side effects. It works better the earlier it’s implanted, and for the dogs that get there, the difference can be life-changing.

What devices exist in 2026?

For dogs: the Milo VNS system

Milo VNS (by Auxilium MD, Texas, USA) is the first VNS system designed specifically for dogs. It consists of:

An implant (pulse generator, less than 0.4 cc) placed on the vagus nerve — no battery replacement needed
A smart collar that wirelessly powers the implant (USB rechargeable)
An app for owners to log seizures and monitor the system
A veterinary portal letting the neurologist adjust parameters remotely, without clinic visits

It’s in an active multicenter clinical trial (AVMA registry VCT26005955) at centers in the US and UK, including the University of Bristol (where the original studies were done) and the University of Glasgow.

Which dogs is it for? Per the trial’s criteria:

Confirmed idiopathic epilepsy
Over 15 kg (33 lbs)
Between 1 and 13 years old
Have failed 2 or more antiseizure medications
At least one seizure in the past 3 months

If your dog doesn’t fit this profile, VNS isn’t an option today — but that doesn’t mean there’s nothing to do (more on that below).

In research: non-invasive VNS

A pilot study (Castillo et al., 2022, Frontiers in Veterinary Science) explored stimulating the vagus nerve through the neck, without an implant — in healthy dogs, as proof of concept. It’s the research line that, if it advances, could lead to devices without surgery. There’s no commercial product yet, but it’s the most promising direction for mass access.

How much does it cost?

Procedures of this kind (implant + diagnostic MRI + follow-up) run, depending on the center, roughly £6,000-10,000 / $4,000-10,000. That’s a significant investment — and it leads to a story everyone in this community should know.

The precedent that proves democratization is possible: CanPacers

In 1991, a group of veterinary cardiologists from the American College of Veterinary Internal Medicine created CanPacers: a program that receives donated human cardiac pacemakers from manufacturers (like Medtronic) and redirects them to dogs that need them, at a cost of around $500.

Since then, thousands of dogs have been treated through this system, and the data from those procedures became published studies that improved veterinary practice worldwide.

Why tell you this in an article about epilepsy? Because CanPacers proved the gap between “advanced technology” and “real access” can be closed with structure: donations, a nonprofit organization, and manufacturer-veterinarian collaboration. It’s the model that could, over time, bring VNS to more dogs and more families.

What this means for you, owner of a dog with epilepsy

If your dog fits the profile (refractory to 2+ medications, over 15 kg): ask your veterinarian about a referral to a board-certified veterinary neurologist, and specifically mention VNS and the Milo trial. Participating centers are in the US and UK — if you’re elsewhere, the neurologist consultation is still worth it: new research programs expand, and your dog’s specific case deserves professional evaluation.

If your dog doesn’t fit (or the cost is out of reach today): that doesn’t mean standing still. The foundation of every successful epilepsy treatment — including candidacy for future therapies — is the same:

Medication properly administered and adjusted by your veterinarian
Consistent logging of every seizure: date, time, duration, type, recovery. The VNS studies require months of seizure diaries as entry criteria — a good log is the gateway to the treatments of the future
A written rescue plan for emergencies
Fluid communication with your veterinary team

If you’re the one asking this question at 3 AM (“there has to be something beyond medication”): the answer today is yes — the science is advancing, there are real devices, active trials, and a proven model of democratization. Drug-resistant canine epilepsy has more hope today than it did five years ago.

FAQ

Does VNS cure epilepsy? No. It significantly reduces seizures in most dogs that respond (over 50% frequency reduction in the studies), but medication continues. It’s adjunctive therapy, not a replacement.

Does it hurt? Side effects? The implant requires surgery under general anesthesia. The most common stimulation side effect is mild coughing during pulses, well tolerated when the current increases gradually.

Does it work for all epilepsy? No. It’s indicated for idiopathic epilepsy (no structural lesion) that’s drug-resistant. Epilepsies with structural causes (tumors, malformations) may require other surgical approaches.

When will it be available in my country? The current trial recruits until June 2027 in the US and UK. Expansion to other countries will depend on results — that’s why trial data matters so much.

What can I do today if I don’t have access? The most valuable thing: log your dog’s seizures well. Every future advance in this field — new devices, new trials, new therapies — needs quality data from thousands of dogs. Your log, combined with thousands of other owners’, is part of how this science moves forward.

Sources

Harcourt-Brown TR, Carter M. Long-term outcome of epileptic dogs treated with implantable vagus nerve stimulators. J Vet Intern Med. 2023;37(6):2102-2108. PMID: 37864369
Harcourt-Brown TR, Carter M. Implantable vagus nerve stimulator settings and short-term adverse effects in epileptic dogs. J Vet Intern Med. 2021;35(5):2350-2358. PMID: 34472639
Castillo G, et al. Transcutaneous Cervical Vagus Nerve Stimulation Induces Changes in the Electroencephalogram and Heart Rate Variability of Healthy Dogs, a Pilot Study. Front Vet Sci. 2022. PMID: 35769324
Nowakowska M, et al. Neurostimulation as a Method of Treatment and a Preventive Measure in Canine Drug-Resistant Epilepsy: Current State and Future Prospects. Front Vet Sci. 2022. PMID: 35782557
AVMA Clinical Trials Registry — Milo VNS Trial, VCT26005955
Oyama MA, et al. Practices and outcomes of artificial cardiac pacing in 154 dogs. J Vet Int Med. 2001;15:229-239
American College of Veterinary Internal Medicine — CanPacers